|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
1,440,000 |
Market
Cap: |
2.07(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.46 - $3.73 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s pipeline consists of two compounds: seclidemstat (SP-2577), a small molecular inhibitor and SP-3164, a small molecular protein degrader. SP-2577 is a small-molecule lysine specific demethylase 1 (LSD1) inhibitor with a scaffold. LSD1 is an enzyme that is, in part, responsible for epigenetic regulation of genes that support cancer growth. SP-3164 is a cereblon binding molecular glue. SP-3164 degrades transcription factors IKZF1 and IKZF3, along with other proteins, resulting in both direct anti-cancer activity and immune-modulating properties. SP-3164 has activity in both hematologic and solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Westphal Christoph H |
President and CEO |
|
2015-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,384,764 |
2,384,764 |
|
- |
|
Sculley John |
Director |
|
2015-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
54,402 |
54,402 |
|
- |
|
Hutt Peter Barton |
Director |
|
2015-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
11,675 |
11,675 |
|
- |
|
Longwood Fund Ii, L.p. |
10% Owner |
|
2015-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,384,764 |
2,384,764 |
|
- |
|
Wessel Thomas |
Chief Medical OfficerOfficer |
|
2015-01-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
37,064 |
|
- |
|
Westphal Christoph H |
President and CEOOfficer |
|
2015-01-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,902,926 |
|
- |
|
156 Records found
|
|
Page 7 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|